

Diagnosing and Treating an Amniotic Fluid Embolism: A Literature Review Amy Howell, BSN, RN, CCRN




OVERVIEW

Unpreventable--devastating--lethal

- "Amniotic fluid embolism (AFE) is the second leading cause of maternal mortality in the USA with an incidence of 1: 15,200 births" (Rezai et al., 2017).
- Incidence and diagnosis differ by region.
- Debris from the amniotic fluid mixes with maternal blood in the pulmonary circulation resulting in a devastating reaction (for some).

TRIAD OF SYMPTOMS




Clark, S. L., Romero, R., Dildy, G. A., Callaghan, W. M., Smiley, R. M., Bracey, A. W., Hankins, G. D., D'Alton, M. E., Foley, M., Pacheco, L. D., Vadhera, R. B., Herlihy, J. P., Berkowitz, R. L., & Belfort, M. A. (2016). Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. American Journal of Obstetrics and Gynecology, 215(4), 408–412. https://doi.org/10.1016/j.ajog.2016.06.037

DIAGNOSIS

- 1. Cardiorespiratory arrest (Hypotension (SBP<90 mm Hg) and respiratory compromise (dyspnea, cyanosis, or SpO2 <90%).
- 2. Disseminated intravascular coagulation (DIC)
- 3. Onset during labor or within 30 minutes of delivery of placenta.
- 4. No fever (\geq 38.0°C) during labor.

(Clark et al.,2016)

Proposed mechanism for Atropine, Ondansetron, and Ketorolac (A-OK) protocol.



Rezai, S., Hughes, A. C., Larsen, T. B., Fuller, P. N., & Henderson, C. E. (2017). Atypical amniotic fluid embolism managed with a novel therapeutic regimen. *Case Reports in Obstetrics & Gynecology*, 1–6. https://doi.org/10.1155/2017/8458375

AMNIOTIC FLUID

•Endogenous mediators: "platelet activating factor, phospholipase A2, endothelin, thromboplastin and prostaglandin" (Lee et al., 2016).

•Anaphylactic reaction \rightarrow pulmonary vasoconstriction

Comorbidities | Signs/ Symptoms | Blood loss & Length of stay Gestation **Treatment Age (years)** Study & type of & race delivery Patient status -Unresponsive Nulliparous 25 days -Pre-eclampsia 3000 ml A: 1mg 34 2/7 weeks O: 4mg -Hypoxic -Uterine fibroids -BP 48/25 Right HF Unknown T: 30mg Normal C-section neurologic race -DIC VA ECMO function. Sent to rehabilitation *TRIAD Massive transfusion VA ECMO G4P2 >41 days -Mental change Kim et 2 previous al., 2020 38 weeks -Seizure miscarriages Left HF Massive (foot drop from Unknown 2 days -Cyanosis ECMO) -Fetal bradycardia Transfusion race C-section *TRIAD Primigravida- -Vitro 600 ml VA ECMO 40 days -Dyspnea Lee et al., 2016 twin pregnancy fertilization -Cyanosis (SpO2 75-40%) Unknown **Impaired** 8min from Massive C-section at 30 -Gestational -Cardiac arrest Transfusion cognitive dyspnea to race weeks-5 days hypertension and (PCO2 15-0) function to arrest diabetes. -DIC nursing home Left HF *TRIAD Parfitt & Unknown G3P2 8 days Not enough 10 minutes after age and race Full term information O: 8 intrauterine no limitations 2019 catheter > -DIC? C-section Sable in 5 -Dyspnea -Cardiac arrest minutes Rezai et 26 G2P1001 -Obese 2000 ml A: 0.2mg 3 days -Dyspnea (for 38 1/7 weeks O: 8mg 8hrs)

-Fever

-HR 144

Diagnosed: Sepsis

Post-delivery:

-Hypotension

-Cardiac arrest

-Hypotension -

Tachycardic

-Cyanosis

-DIC

-Cyanosis

-Gestational

diabetes

Hispanic

Wise et

al., 2016

gestation

C-Section

Full term

assisted

Vaginal,

39 wk 4 days

Primagravida -

CASE STUDIES

METHODS

Unknonwn

2500 ml

RHF

K: 15mg

Transfusion

-V-V ECMO

-V-A ECMO

Hemodialysis

-Bakri balloon

embolization

-Artery

18 days

On HD for 3

	Literatur	re Search	
atabases: Unio Google Scholar	n University Library	(Ebscohost, ScienceDirect) and	
		torolac or Toradol, ondansetron or membrane oxygenation or ECMO	
		\	
	Search resul	lts combined	
	(n=5	,234)	
	Articles screened by title, abstract, language, and limited to full-text articles between 2013-2020		
	(n=	101)	
	Articles included	Articles excluded (n=95)	
(n=6)		Exclusion criteria (did not include case study): 89	
		1000 0000 1000	

LAB WORK

Modified International Society on Thrombosis and Hemostasis scoring system for overt disseminated intravascular coagulation in pregnancy

Platelet	PT/INR	Fibrinogen
>100,000/ml = 0	<25% increase = 0	>200 mg/L = 0
<100,000/ml=1	25-50% increase = 1	<200 mg/L = 1
<50,000/ml=2	>50% increase = 2	

Score ≥ 3 =DIC in pregnancy

Clark, S. L., Romero, R., Dildy, G. A., Callaghan, W. M., Smiley, R. M., Bracey, A. W., Hankins, G. D., D'Alton, M. E., Foley, M., Pacheco, L. D., Vadhera, R. B., Herlihy, Berkowitz, R. L., & Belfort, M. A. (2016). Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. *American Journal of Obstetrics and Gynecology*, 215(4), 408–412. https://doi.org/10.1016/j.ajog.2016.06.037

IMPLEMENTATION

Question: What is the satisfaction level of student registered nurse anesthetists regarding the guideline presented for the diagnosis and treatment of AFE?

• 21 people participated

Survey	Response (%)	
Overall, how would you	Excellent 95.24	
rate the course?	Very good 4.76	
How confident do you	Extremely 33.33	
feel about applying the	Very 61.90	
material covered in	Somewhat 4.76	
practice?		
How useful were the	Extremely 90.48	
course materials?	Very 4.76	
	Somewhat 4.76	
How clearly did your	Extremely 80.95	
instructor explain the	Very 19.05	
course material?		

Survey	Response %
The speed with which	Much too fast 4.76
your instructor presented	Too fast 4.76
the course material	The right amount 90.48
How well did your	Extremely well 76.19
instructor answer	Very well 23.81
students' questions?	
How comfortable did you	Extremely 76.49
feel voicing your opinions	Very 23.81
in class?	
How helpful were the	Extremely 70
visual aids and	Very 25
PowerPoint?	Somewhat 5

CONCLUSION

- Rare emergency requiring rapid recognition and treatment
- Triad of symptoms: hypoxia, cardiovascular collapse (hypotension), and coagulopathy (DIC)
- Atypical presentations exist (seizures and frothy pink sputum).
- Both the novel A-OK regimen and the more aggressive ECMO therapy have positive patient outcomes.
- More data needs to be submitted to study the disease process further and determine the cause, treatment, risk factors, diagnostic criteria, and biomarkers.

REFERENCES

- Clark, S. L., Romero, R., Dildy, G. A., Callaghan, W. M., Smiley, R. M., Bracey, A. W., Hankins, G. D., D'Alton, M. E., Foley, M., Pacheco, L. D., Vadhera, R. B., Herlihy, J. P., Berkowitz, R. L., & Belfort, M. A. (2016). Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. *American Journal of Obstetrics and Gynecology*, 215(4), 408–412. https://doi.org/10.1016/j.ajog.2016.06.037
- Gitman, R., Bachar, B., & Mendenhall, B. (2019). Amniotic fluid embolism treated with veno-arterial extracorporeal membrane oxygenation. *Case Reports in Critical Care*, 1–5. https://doi.org/10.1155/2019/4589636
- Kim, J. W., Kim, J. H., Kim, T. W., Ryu, K. H., Park, S. G., Jeong, C. Y., Choi, J. H., & Park, D. H. (2020). Successful resuscitation by using extracorporeal membrane oxygenation in a patient with amniotic fluid embolism: a case report. *The Journal of International Medical Research*, 48(2). https://doi.org/10.1177%2F0300060520903640
- Lee, J. H., Jang, H. J., Park, J. H., Kim, Y. K., Min, H. K., Kim, S.Y., & Kim, H. (2016). Use of extracorporeal membrane oxygenation in a fulminant course of amniotic fluid embolism syndrome immediately after cesarean delivery. *Korean Journal of Critical Care Medicine*, 31(3), 256–261. https://doi.org/10.4266/kjccm.2016.00213
- Parfitt, S. & Roth, C. K. (2019). A novel approach to amniotic fluid embolism treatment through use of the atropine, ondansetron, and ketorolac protocol. *Journal of Obstetric, Gynecologic & Neonatal Nursing*, 48(3), S164-S165. https://doi.org/10.1016/j.jogn.2019.04.272
- Rezai, S., Hughes, A. C., Larsen, T. B., Fuller, P. N., & Henderson, C. E. (2017). Atypical amniotic fluid embolism managed with a novel therapeutic regimen. *Case Reports in Obstetrics & Gynecology*, 1–6. https://doi.org/10.1155/2017/8458375 Sadera, G. & Vasudevan, B. (2015). Amniotic fluid embolism. *Journal of Obstetric Anesthesia and Critical Care*, 5(1), 3-8. https://doi.org/10.4103/2249-4472.155192
- Tuffnell, D. J., & Slemeck, E. (2017). Amniotic fluid embolism. *Obstetrics, Gynaecology & Reproductive Medicine*, 27(3), 86–90. https://doi.org/10.1016/j.ogrm.2016.12.006
- Wise, E. M., Harika, R., & Zahir, F. (2016). Successful recovery after amniotic fluid embolism in a patient undergoing vacuum-assisted vaginal delivery. *Journal of Clinical Anesthesia*, 34, 557–561. https://doi.org/10.1016/j.jclinane.2016.06.021